Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-10

AUTHORS

Yasunobu Shibasaki, Takashi Nishiue, Hiroya Masaki, Koji Tamura, Noriko Matsumoto, Yasukiyo Mori, Mitsushige Nishikawa, Hiroaki Matsubara, Toshiji Iwasaka

ABSTRACT

Myocardial fibrosis commonly occurs in patients with end-stage renal disease (ESRD) and has proven to be an important predictor for cardiovascular events. In experimental settings, angiotensin II type 1 receptor (AT1-R) antagonists have been shown to have anti-fibrotic effects on the myocardium independent of their antihypertensive effects. In this study, to investigate whether the AT1-R antagonist losartan would have such anti-fibrotic effects in patients, we administered losartan or, for purpose of comparison, the angiotensin-converting enzyme enalapril or Ca2+-antagonist amlodipine to patients with ESRD. Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13). Ultrasonic integrated backscatter (IBS) and serological markers of collagen type I synthesis and degradation were used to assess the degree of myocardial fibrosis just before and after 6 months of treatment. There were no significant differences in antihypertensive effects among the three agents. In the enalapril- and amlodipine-treated groups, the mean calibrated IBS values increased significantly after 6 months of treatment (enalapril: −31.6±1.3 to −29.4±1.2 dB, p=0.011; amlodipine: −30.6±1.4 to −27.2±1.2 dB, p=0.012). However, the mean calibrated IBS values in the losartan-treated group did not increase after 6 months of treatment (−31.2±1.7 to −31.3±1.4 dB, p=0.88). The ratio of the serum concentration of procollagen type I carboxy-terminal peptide to the serum concentration of collagen type I pyridinoline cross-linked carboxy-terminal telopeptide was significantly reduced in the losartan-treated group (42.6±4.6 to 34.4±3.6, p=0.038). The present study indicates that losartan more effectively suppresses myocardial fibrosis in patients with ESRD than does enalapril or amlodipine despite a comparable antihypertensive effect among the three drugs. More... »

PAGES

787-795

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1291/hypres.28.787

DOI

http://dx.doi.org/10.1291/hypres.28.787

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033693594

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16471172


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amlodipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Collagen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Echocardiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enalapril", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Failure, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Losartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptide Fragments", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Procollagen", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shibasaki", 
        "givenName": "Yasunobu", 
        "id": "sg:person.01332673465.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332673465.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishiue", 
        "givenName": "Takashi", 
        "id": "sg:person.01330631462.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330631462.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masaki", 
        "givenName": "Hiroya", 
        "id": "sg:person.01311276161.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311276161.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamura", 
        "givenName": "Koji", 
        "id": "sg:person.01016424677.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016424677.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumoto", 
        "givenName": "Noriko", 
        "id": "sg:person.0701616065.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701616065.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hypertension and Nephrology, Kyoto Prefectural University School of Medicine, Kyoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258797.6", 
          "name": [
            "Department of Hypertension and Nephrology, Kyoto Prefectural University School of Medicine, Kyoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mori", 
        "givenName": "Yasukiyo", 
        "id": "sg:person.01150521101.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150521101.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishikawa", 
        "givenName": "Mitsushige", 
        "id": "sg:person.01033035076.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033035076.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258797.6", 
          "name": [
            "Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsubara", 
        "givenName": "Hiroaki", 
        "id": "sg:person.013716016572.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013716016572.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine II, Kansai Medical University, Moriguchi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410783.9", 
          "name": [
            "Department of Medicine II, Kansai Medical University, Moriguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwasaka", 
        "givenName": "Toshiji", 
        "id": "sg:person.01027604020.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027604020.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00226785", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023336965", 
          "https://doi.org/10.1007/bf00226785"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-10", 
    "datePublishedReg": "2005-10-01", 
    "description": "Myocardial fibrosis commonly occurs in patients with end-stage renal disease (ESRD) and has proven to be an important predictor for cardiovascular events. In experimental settings, angiotensin II type 1 receptor (AT1-R) antagonists have been shown to have anti-fibrotic effects on the myocardium independent of their antihypertensive effects. In this study, to investigate whether the AT1-R antagonist losartan would have such anti-fibrotic effects in patients, we administered losartan or, for purpose of comparison, the angiotensin-converting enzyme enalapril or Ca2+-antagonist amlodipine to patients with ESRD. Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13). Ultrasonic integrated backscatter (IBS) and serological markers of collagen type I synthesis and degradation were used to assess the degree of myocardial fibrosis just before and after 6 months of treatment. There were no significant differences in antihypertensive effects among the three agents. In the enalapril- and amlodipine-treated groups, the mean calibrated IBS values increased significantly after 6 months of treatment (enalapril: \u221231.6\u00b11.3 to \u221229.4\u00b11.2 dB, p=0.011; amlodipine: \u221230.6\u00b11.4 to \u221227.2\u00b11.2 dB, p=0.012). However, the mean calibrated IBS values in the losartan-treated group did not increase after 6 months of treatment (\u221231.2\u00b11.7 to \u221231.3\u00b11.4 dB, p=0.88). The ratio of the serum concentration of procollagen type I carboxy-terminal peptide to the serum concentration of collagen type I pyridinoline cross-linked carboxy-terminal telopeptide was significantly reduced in the losartan-treated group (42.6\u00b14.6 to 34.4\u00b13.6, p=0.038). The present study indicates that losartan more effectively suppresses myocardial fibrosis in patients with ESRD than does enalapril or amlodipine despite a comparable antihypertensive effect among the three drugs.", 
    "genre": "article", 
    "id": "sg:pub.10.1291/hypres.28.787", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Japanese Society of Hypertension", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "keywords": [
      "end-stage renal disease", 
      "months of treatment", 
      "anti-fibrotic effects", 
      "myocardial fibrosis", 
      "antihypertensive effect", 
      "renal disease", 
      "receptor antagonist", 
      "serum concentrations", 
      "ultrasonic integrated backscatter", 
      "cross-linked carboxy-terminal telopeptide", 
      "angiotensin II type 1 receptor antagonist", 
      "amlodipine-treated group", 
      "type 1 receptor antagonist", 
      "carboxy-terminal telopeptide", 
      "procollagen type I carboxy-terminal peptide", 
      "IBS values", 
      "angiotensin II receptor antagonist", 
      "AT1-R antagonist losartan", 
      "comparable antihypertensive effects", 
      "collagen type I synthesis", 
      "integrated backscatter", 
      "type I synthesis", 
      "cardiovascular events", 
      "ESRD patients", 
      "antagonist losartan", 
      "serological markers", 
      "losartan", 
      "patients", 
      "biochemical markers", 
      "fibrosis", 
      "carboxy-terminal peptide", 
      "collagen type I", 
      "months", 
      "significant differences", 
      "amlodipine", 
      "antagonist", 
      "important predictor", 
      "treatment", 
      "disease", 
      "type I", 
      "present study", 
      "markers", 
      "group", 
      "hypertension", 
      "enalapril", 
      "angiotensin", 
      "telopeptide", 
      "myocardium", 
      "experimental settings", 
      "drugs", 
      "effect", 
      "predictors", 
      "study", 
      "Ca2", 
      "concentration", 
      "agents", 
      "setting", 
      "peptides", 
      "assessment", 
      "differences", 
      "events", 
      "enzyme", 
      "purpose", 
      "means", 
      "purpose of comparison", 
      "values", 
      "degree", 
      "impact", 
      "ratio", 
      "comparison", 
      "synthesis", 
      "degradation", 
      "backscatter", 
      "II type 1 receptor (AT1-R) antagonists", 
      "such anti-fibrotic effects", 
      "I synthesis", 
      "type I carboxy-terminal peptide", 
      "I carboxy-terminal peptide", 
      "II Receptor Antagonist"
    ], 
    "name": "Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers", 
    "pagination": "787-795", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033693594"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1291/hypres.28.787"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16471172"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1291/hypres.28.787", 
      "https://app.dimensions.ai/details/publication/pub.1033693594"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_409.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1291/hypres.28.787"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1291/hypres.28.787'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1291/hypres.28.787'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1291/hypres.28.787'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1291/hypres.28.787'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      22 PREDICATES      123 URIs      114 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1291/hypres.28.787 schema:about N1c51a23f297c4a929fbdb9418ecdc107
2 N29b6b115a6cf4a778dd5edd8070f3585
3 N2e309fcd31f948d3a1c5afe5907728f9
4 N2f58bddcf5c0401aa55ff6dc3f7cbc53
5 N653f594a48134473a4a04d3332171346
6 N66aa7ec9b481426688706296d7df40f7
7 N6957ae22f84c43718dde58498d50e5ec
8 N6970b15a17274594965b05800e417e1d
9 N6ea9048d155941369cfca4abab2aa74b
10 N82e73a7dffb84b13a4b862cc7d88cb52
11 N87cf8ac3cf5a44629c751cd38704e9a2
12 Nb72f6a60b4094b45b5cd52ce740be4b2
13 Nb7943142aafa436eb4c0bc681147602c
14 Nc2ed66b125064284bde959abe3d9f692
15 Nd12ef7e0907942e9a06752036805882a
16 Nf293778b74404b4091c0f4c965959577
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N46b7d9dc456543fbb79ef7935f547870
20 schema:citation sg:pub.10.1007/bf00226785
21 schema:datePublished 2005-10
22 schema:datePublishedReg 2005-10-01
23 schema:description Myocardial fibrosis commonly occurs in patients with end-stage renal disease (ESRD) and has proven to be an important predictor for cardiovascular events. In experimental settings, angiotensin II type 1 receptor (AT1-R) antagonists have been shown to have anti-fibrotic effects on the myocardium independent of their antihypertensive effects. In this study, to investigate whether the AT1-R antagonist losartan would have such anti-fibrotic effects in patients, we administered losartan or, for purpose of comparison, the angiotensin-converting enzyme enalapril or Ca2+-antagonist amlodipine to patients with ESRD. Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13). Ultrasonic integrated backscatter (IBS) and serological markers of collagen type I synthesis and degradation were used to assess the degree of myocardial fibrosis just before and after 6 months of treatment. There were no significant differences in antihypertensive effects among the three agents. In the enalapril- and amlodipine-treated groups, the mean calibrated IBS values increased significantly after 6 months of treatment (enalapril: −31.6±1.3 to −29.4±1.2 dB, p=0.011; amlodipine: −30.6±1.4 to −27.2±1.2 dB, p=0.012). However, the mean calibrated IBS values in the losartan-treated group did not increase after 6 months of treatment (−31.2±1.7 to −31.3±1.4 dB, p=0.88). The ratio of the serum concentration of procollagen type I carboxy-terminal peptide to the serum concentration of collagen type I pyridinoline cross-linked carboxy-terminal telopeptide was significantly reduced in the losartan-treated group (42.6±4.6 to 34.4±3.6, p=0.038). The present study indicates that losartan more effectively suppresses myocardial fibrosis in patients with ESRD than does enalapril or amlodipine despite a comparable antihypertensive effect among the three drugs.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N0b9f3bbb55f44b949e9dde147425843d
28 N567293d8ca6442ec8009cf5b3c6889db
29 sg:journal.1313717
30 schema:keywords AT1-R antagonist losartan
31 Ca2
32 ESRD patients
33 I carboxy-terminal peptide
34 I synthesis
35 IBS values
36 II Receptor Antagonist
37 II type 1 receptor (AT1-R) antagonists
38 agents
39 amlodipine
40 amlodipine-treated group
41 angiotensin
42 angiotensin II receptor antagonist
43 angiotensin II type 1 receptor antagonist
44 antagonist
45 antagonist losartan
46 anti-fibrotic effects
47 antihypertensive effect
48 assessment
49 backscatter
50 biochemical markers
51 carboxy-terminal peptide
52 carboxy-terminal telopeptide
53 cardiovascular events
54 collagen type I
55 collagen type I synthesis
56 comparable antihypertensive effects
57 comparison
58 concentration
59 cross-linked carboxy-terminal telopeptide
60 degradation
61 degree
62 differences
63 disease
64 drugs
65 effect
66 enalapril
67 end-stage renal disease
68 enzyme
69 events
70 experimental settings
71 fibrosis
72 group
73 hypertension
74 impact
75 important predictor
76 integrated backscatter
77 losartan
78 markers
79 means
80 months
81 months of treatment
82 myocardial fibrosis
83 myocardium
84 patients
85 peptides
86 predictors
87 present study
88 procollagen type I carboxy-terminal peptide
89 purpose
90 purpose of comparison
91 ratio
92 receptor antagonist
93 renal disease
94 serological markers
95 serum concentrations
96 setting
97 significant differences
98 study
99 such anti-fibrotic effects
100 synthesis
101 telopeptide
102 treatment
103 type 1 receptor antagonist
104 type I
105 type I carboxy-terminal peptide
106 type I synthesis
107 ultrasonic integrated backscatter
108 values
109 schema:name Impact of the Angiotensin II Receptor Antagonist, Losartan, on Myocardial Fibrosis in Patients with End-Stage Renal Disease: Assessment by Ultrasonic Integrated Backscatter and Biochemical Markers
110 schema:pagination 787-795
111 schema:productId N661e5bbfdb19440995b269ccb21bec30
112 N805b4d0ffc424fa29bda5ee3d9bc4b2b
113 Nd5c62210432e412aa163caa9a6fe0cce
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033693594
115 https://doi.org/10.1291/hypres.28.787
116 schema:sdDatePublished 2021-11-01T18:08
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N6469a1f38877432b8c228b25ef2ee2f7
119 schema:url https://doi.org/10.1291/hypres.28.787
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N0b9f3bbb55f44b949e9dde147425843d schema:volumeNumber 28
124 rdf:type schema:PublicationVolume
125 N135c4d42428c4e05bac866ba2439415f rdf:first sg:person.01016424677.17
126 rdf:rest N40350b291f8f4860999c429244bf32f6
127 N1c51a23f297c4a929fbdb9418ecdc107 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Procollagen
129 rdf:type schema:DefinedTerm
130 N29b6b115a6cf4a778dd5edd8070f3585 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Female
132 rdf:type schema:DefinedTerm
133 N2e309fcd31f948d3a1c5afe5907728f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Fibrosis
135 rdf:type schema:DefinedTerm
136 N2f58bddcf5c0401aa55ff6dc3f7cbc53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Peptide Fragments
138 rdf:type schema:DefinedTerm
139 N3190acd41c234639a008f3f838e66c39 rdf:first sg:person.01027604020.40
140 rdf:rest rdf:nil
141 N40350b291f8f4860999c429244bf32f6 rdf:first sg:person.0701616065.17
142 rdf:rest Ncc6a8c7866ff41a3991e410548522af6
143 N46b7d9dc456543fbb79ef7935f547870 rdf:first sg:person.01332673465.19
144 rdf:rest Nc04c7f423fd248fa833a3efbbeb17895
145 N567293d8ca6442ec8009cf5b3c6889db schema:issueNumber 10
146 rdf:type schema:PublicationIssue
147 N6469a1f38877432b8c228b25ef2ee2f7 schema:name Springer Nature - SN SciGraph project
148 rdf:type schema:Organization
149 N653f594a48134473a4a04d3332171346 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Double-Blind Method
151 rdf:type schema:DefinedTerm
152 N65cbca1d74384d938499f007e8efb9ef rdf:first sg:person.013716016572.67
153 rdf:rest N3190acd41c234639a008f3f838e66c39
154 N661e5bbfdb19440995b269ccb21bec30 schema:name doi
155 schema:value 10.1291/hypres.28.787
156 rdf:type schema:PropertyValue
157 N66aa7ec9b481426688706296d7df40f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Male
159 rdf:type schema:DefinedTerm
160 N6957ae22f84c43718dde58498d50e5ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Angiotensin II Type 1 Receptor Blockers
162 rdf:type schema:DefinedTerm
163 N6970b15a17274594965b05800e417e1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Collagen
165 rdf:type schema:DefinedTerm
166 N6ea9048d155941369cfca4abab2aa74b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Losartan
168 rdf:type schema:DefinedTerm
169 N805b4d0ffc424fa29bda5ee3d9bc4b2b schema:name pubmed_id
170 schema:value 16471172
171 rdf:type schema:PropertyValue
172 N82e73a7dffb84b13a4b862cc7d88cb52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Kidney Failure, Chronic
174 rdf:type schema:DefinedTerm
175 N87cf8ac3cf5a44629c751cd38704e9a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Echocardiography
177 rdf:type schema:DefinedTerm
178 N8aae674ba073464dbbf8b41a90ceea55 rdf:first sg:person.01033035076.70
179 rdf:rest N65cbca1d74384d938499f007e8efb9ef
180 Nacfcbf850e65471a9902fa4f4c46f203 rdf:first sg:person.01311276161.06
181 rdf:rest N135c4d42428c4e05bac866ba2439415f
182 Nb72f6a60b4094b45b5cd52ce740be4b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Middle Aged
184 rdf:type schema:DefinedTerm
185 Nb7943142aafa436eb4c0bc681147602c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Enalapril
187 rdf:type schema:DefinedTerm
188 Nc04c7f423fd248fa833a3efbbeb17895 rdf:first sg:person.01330631462.45
189 rdf:rest Nacfcbf850e65471a9902fa4f4c46f203
190 Nc2ed66b125064284bde959abe3d9f692 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Myocardium
192 rdf:type schema:DefinedTerm
193 Ncc6a8c7866ff41a3991e410548522af6 rdf:first sg:person.01150521101.97
194 rdf:rest N8aae674ba073464dbbf8b41a90ceea55
195 Nd12ef7e0907942e9a06752036805882a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Amlodipine
197 rdf:type schema:DefinedTerm
198 Nd5c62210432e412aa163caa9a6fe0cce schema:name dimensions_id
199 schema:value pub.1033693594
200 rdf:type schema:PropertyValue
201 Nf293778b74404b4091c0f4c965959577 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Humans
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
208 schema:name Clinical Sciences
209 rdf:type schema:DefinedTerm
210 sg:journal.1313717 schema:issn 0916-9636
211 1348-4214
212 schema:name Hypertension Research
213 schema:publisher Japanese Society of Hypertension
214 rdf:type schema:Periodical
215 sg:person.01016424677.17 schema:affiliation grid-institutes:grid.410783.9
216 schema:familyName Tamura
217 schema:givenName Koji
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016424677.17
219 rdf:type schema:Person
220 sg:person.01027604020.40 schema:affiliation grid-institutes:grid.410783.9
221 schema:familyName Iwasaka
222 schema:givenName Toshiji
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027604020.40
224 rdf:type schema:Person
225 sg:person.01033035076.70 schema:affiliation grid-institutes:grid.410783.9
226 schema:familyName Nishikawa
227 schema:givenName Mitsushige
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033035076.70
229 rdf:type schema:Person
230 sg:person.01150521101.97 schema:affiliation grid-institutes:grid.258797.6
231 schema:familyName Mori
232 schema:givenName Yasukiyo
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150521101.97
234 rdf:type schema:Person
235 sg:person.01311276161.06 schema:affiliation grid-institutes:grid.410783.9
236 schema:familyName Masaki
237 schema:givenName Hiroya
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311276161.06
239 rdf:type schema:Person
240 sg:person.01330631462.45 schema:affiliation grid-institutes:grid.410783.9
241 schema:familyName Nishiue
242 schema:givenName Takashi
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330631462.45
244 rdf:type schema:Person
245 sg:person.01332673465.19 schema:affiliation grid-institutes:grid.410783.9
246 schema:familyName Shibasaki
247 schema:givenName Yasunobu
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332673465.19
249 rdf:type schema:Person
250 sg:person.013716016572.67 schema:affiliation grid-institutes:grid.258797.6
251 schema:familyName Matsubara
252 schema:givenName Hiroaki
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013716016572.67
254 rdf:type schema:Person
255 sg:person.0701616065.17 schema:affiliation grid-institutes:grid.410783.9
256 schema:familyName Matsumoto
257 schema:givenName Noriko
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701616065.17
259 rdf:type schema:Person
260 sg:pub.10.1007/bf00226785 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023336965
261 https://doi.org/10.1007/bf00226785
262 rdf:type schema:CreativeWork
263 grid-institutes:grid.258797.6 schema:alternateName Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan
264 Department of Hypertension and Nephrology, Kyoto Prefectural University School of Medicine, Kyoto, Japan
265 schema:name Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan
266 Department of Hypertension and Nephrology, Kyoto Prefectural University School of Medicine, Kyoto, Japan
267 rdf:type schema:Organization
268 grid-institutes:grid.410783.9 schema:alternateName Department of Medicine II, Kansai Medical University, Moriguchi, Japan
269 schema:name Department of Medicine II, Kansai Medical University, Moriguchi, Japan
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...